ASH 2023 | The safety & efficacy of copanlisib + nivolumab in patients with RT and tNHL: a chemo-free approach
Alexey Danilov, MD, PhD, City of Hope, Duarte, CA, discusses the Phase I trial (NCT03884998) investigating the maximum tolerated dose (MTD) of copanlisib, a P13K inhibitor, combined with nivolumab, a PD-1 antagonist, to treat patients with Richter’s transformation (RT) or transformed non-Hodgkin lymphoma (tNHL). Prof. Danilov outlines the exploratory objectives of the trial, including determining preliminary efficacy, dose-limiting toxicities (DLT), and T-cell functionality. Although copanlisib has now been withdrawn from the market, this study highlights that a chemotherapy-free approach is feasible in this patient population. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Consultancy: MEI, Lilly Oncology, Nurix, Abbvie, Beigene, Janssen, Astra Zeneca, Bristol Meyers Squibb, Genentech, GenMab, Merck
Research Funding: MEI, Lilly Oncology, Cyclacel, Bayer, Nurix, Abbvie, Beigene, Astra Zeneca, Bristol Meyers Squibb, GenMab
